National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

This is VAERS ID 350028

(NOTE: This result is from the 8/14/2018 version of the VAERS database)

Case Details

VAERS ID: 350028 (history)  
Form: Version 1.0  
Age: 22.0  
Sex: Female  
Location: Foreign  
   Days after vaccination:21
Submitted: 2009-06-24
   Days after onset:116
Entered: 2009-06-24
Vaccin­ation / Manu­facturer Lot / Dose Site / Route

Administered by: Other       Purchased by: Other
Symptoms: Optic neuropathy, Papilloedema
SMQs:, Guillain-Barre syndrome (broad), Optic nerve disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, 0 days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions:
Diagnostic Lab Data: UNK
CDC Split Type: B0579359A

Write-up: This case was reported by a regulatory authority (MP20090384, MP0900293) and described the occurrence of optic neuropathy in a 22-year-old female subject who was vaccinated with ENGERIX B (GlaxoSmithKline), GARDASIL (non-GSK). Medical conditions and concurrent medications were unspecified. Previous vaccination included an unspecified dose of GARDASIL given in December 2008. On 06 February 2009, the subject received unspecified dose of ENGERIX B (intramuscular, injection site and batch unknown). In February 2009, on unspecified date, the subject received unspecified dose of GARDASIL (intramuscular, injection site and batch unknown). On 27 February 2009, less than one month after vaccination with GARDASIL and 21 days after vaccination with ENGERIX B, the subject experienced optic neuropathy and papilloedema (NOS). On 06 March 2009, the subject received another dose of ENGERIX B (intramuscular, injection site and batch unknown). The regulatory agency noticed that the events led to hospitalisation and or prolonged hospitalisation. At the time of reporting, the events were improved. The regulatory authority considered optic neuropathy and papilloedema as unlikely related to vaccination with ENGERIX B and GARDASIL, according to the method of imputability.

New Search

Link To This Search Result:

Copyright © 2019 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166